Duley
John Wiley & Sons
e druk, 2001
9780727915993
Clinical Trials
Specificaties
Paperback, 144 blz.
|
Engels
John Wiley & Sons |
e druk, 2001
ISBN13: 9780727915993
Rubricering
Verwachte levertijd ongeveer 16 werkdagen
Samenvatting
This authoritative book discusses the use of clinical trials in health sciences including why they are important, how to do them and how they can be used most relevantly in health care for the future.
The chapters are based on papers given at an Oxford seminar by leading figures in this field and the discussions that followed.
The book will be of particular interest to clinical trialists and the pharmaceutical industry.
Specificaties
Inhoudsopgave
Contributors.
<p>Foreword.</p>
<p>Preface.</p>
<p>Acknowledgements.</p>
<p>Comparing like with like and the development of randomisation.</p>
<p>Why we need randomised controlled trials.</p>
<p>Keeping track of trial reports; the experience of The Cochrane Trials Register.</p>
<p>What have we learned from 50 years of randomised trials for people with schizophrenia.</p>
<p>Big is still beautiful: why we still need large simple trials.</p>
<p>Factors that limit the number, quality and progress of randomised trials.</p>
<p>The nuts and bolts of doing trials.</p>
<p>Building resources for randomised trials.</p>
<p>The role of data monitoring committees.</p>
<p>Bayesian perspectives on the ethics of trials.</p>
<p>"Empowering" patient choice about participation in trials?.</p>
<p>Index</p>
<p>Foreword.</p>
<p>Preface.</p>
<p>Acknowledgements.</p>
<p>Comparing like with like and the development of randomisation.</p>
<p>Why we need randomised controlled trials.</p>
<p>Keeping track of trial reports; the experience of The Cochrane Trials Register.</p>
<p>What have we learned from 50 years of randomised trials for people with schizophrenia.</p>
<p>Big is still beautiful: why we still need large simple trials.</p>
<p>Factors that limit the number, quality and progress of randomised trials.</p>
<p>The nuts and bolts of doing trials.</p>
<p>Building resources for randomised trials.</p>
<p>The role of data monitoring committees.</p>
<p>Bayesian perspectives on the ethics of trials.</p>
<p>"Empowering" patient choice about participation in trials?.</p>
<p>Index</p>